Sensei Biotherapeutics (SNSE) to Release Earnings on Tuesday

Sensei Biotherapeutics (NASDAQ:SNSE) is anticipated to post its Q4 2025 results before the market opens on Tuesday, May 5th. Analysts expect Sensei Biotherapeutics to post earnings of ($0.62) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, April 10, 2026 at 10:30 AM ET.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings data on Monday, March 30th. The company reported ($3.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.81) by $1.07. On average, analysts expect Sensei Biotherapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sensei Biotherapeutics Stock Performance

Sensei Biotherapeutics stock opened at $26.96 on Friday. Sensei Biotherapeutics has a fifty-two week low of $5.25 and a fifty-two week high of $36.76. The company has a market capitalization of $36.15 million, a P/E ratio of -1.62 and a beta of -0.18. The stock has a 50-day simple moving average of $30.58 and a 200-day simple moving average of $17.22.

Institutional Trading of Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned about 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 10.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Friday, April 24th. Leerink Partners assumed coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They issued an “outperform” rating and a $50.00 target price for the company. Finally, Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $40.00.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.